Sarcoma News
Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading
Cancer Deaths on the Decline (February 11, 2013)Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading
Shorter Chemotherapy Intervals Effective in Ewing Sarcoma (November 1, 2012)In patients with localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than chemotherapy administered every three weeks, with no increase in toxicity, according to the results of a study published in the Journal of Clinical... Continue Reading
Regorafenib May Expand GIST Treatment Options (June 13, 2012)Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading
Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading
Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading
FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors (February 29, 2012)In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better survival than one year of adjuvant treatment among... Continue Reading
Do Complementary Therapies Work? – Ask the expert about herbs, acupuncture, and other complementary therapies (November 4, 2011)Live Web Chat with Barrie R. Cassileth, PhD, Chief, Integrative Medicine Service; Laurance S. Rockefeller Chair Integrative Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), click here for Dr. Cassileth’s bio Dr. Cassileth is a world-renowned... Continue Reading
CancerConnect Live Web Chat with Dr. Sidransky on Picking the Cancer Treatment That Works Best for You on Wednesday, November 2, 2011 at 6:00 PM Eastern Time (October 25, 2011)Picking the Cancer Treatment That Works Best for You- Ask the Expert about Personalized Medicine Live Web Chat with David Sidransky, MD, Johns Hopkins Medicine, Baltimore, MD, click here for bio Dr. David Sidransky is an award-winning oncologist and... Continue Reading
Chemotherapy During Pregnancy Not Linked with Developmental Problems in Kids (October 4, 2011)According to a study presented at the 2011 European Multidisciplinary Cancer Congress, children born to women who received chemotherapy during pregnancy do not appear to have an increased risk of heart or cognitive problems. Since relatively few women... Continue Reading
Latest Sarcoma News By Stage
Ewing's Sarcoma Overview
Shorter Chemotherapy Intervals Effective in Ewing Sarcoma (November 1, 2012)
In patients with localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than chemotherapy administered every three weeks, with no increase in toxicity, according to the results of a study published in the Journal of Clinical... Continue Reading
Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence (February 19, 2010)Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute. As cancer treatment has improved and evolved, the number... Continue Reading
More Ewing's Sarcoma OverviewGeneral Sarcoma
Regorafenib May Expand GIST Treatment Options (June 13, 2012)
Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading
FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors (February 29, 2012)In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better survival than one year of adjuvant treatment among... Continue Reading
Halaven Promising in Soft-Tissue Sarcoma (September 26, 2011)The chemotherapy drug Halaven™ (eribulin mesylate) may be a promising therapy for certain types of soft-tissue sarcoma. These findings were recently reported in the Lancet Oncology. Halaven—which was derived from a marine sponge—is a chemotherapy... Continue Reading
Stay on Top of Your Family History of Cancer (July 15, 2011)People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading
Three Years of Treatment with Gleevec Improves Survival in Gastrointestinal Stromal Tumors (GIST) (June 9, 2011)Treatment with Gleevec® (imatinib) for 3 years following surgery significantly improves survival compared with the standard one-year therapy for patients with gastrointestinal stromal tumors (GIST). GIST is a type of soft tissue sarcoma that develops... Continue Reading
More General SarcomaSoft Tissue Sarcomas
Regorafenib May Expand GIST Treatment Options (June 13, 2012)
Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading
More Soft Tissue Sarcomas